Neelikon Food Dyes & Chemicals Ltd. Overview
Neelikon is a Mumbai-headquartered, promoter-owned specialty colourant manufacturer. It has a four-decade record in high-purity synthetic food, drug and cosmetic (FD&C / D&C) dyes and lakes. It also makes specialty fluorescent dyes, and is expanding into natural colours and titanium-dioxide-free opacity alternatives. The company describes itself as one of the world's top three producers of food colours, cosmetic pigments and fluorescent dyes. Manufacturing is anchored at MIDC Dhatav, Roha (Maharashtra), with a combined 4,625 MTPA capacity including manufacturing partners. A greenfield plant at Saykha, Gujarat was commissioned in March 2024. Wholly owned subsidiaries in the UK, the Netherlands, China and (most recently) the USA provide local stock and technical service. The company says its products reach over 100 countries. Financially it is small (about INR 465 crore consolidated revenue in FY2025) but conservatively run: it has no long-term debt, interest coverage near 50x and an A+/A1+ credit profile. Its central strategic exposure is the global regulatory shift away from petroleum-based synthetic dyes.
What the company does
Neelikon manufactures and sells colourants. These are chemical and, increasingly, natural substances that impart colour to food, beverages, pharmaceuticals, cosmetics, personal care, home care, stationery and inkjet inks, and some industrial applications.
ICRA's company description, repeated across its 2023, 2025 and 2026 rationales, covers dyes for six uses:
-
food
-
pharmaceuticals
-
cosmetics
-
inkjet ink
-
writing ink
-
fluorescent pigments
Trade-show listings from 2025–2026 describe a broader range:
-
US FDA-certified dyes and lakes
-
pigments
-
iron oxides
-
titanium dioxide
-
water-soluble and oil-soluble dyes
-
natural colours
-
titanium-dioxide-free alternatives
-
customised blends
Company's own description (paraphrased)
Neelikon's exhibitor profiles (Maghreb Pharma; Fi Europe 2025) describe it as follows:
-
An ISO 9001, ISO 14001, ISO 45001 and FSSC 22000-certified colour manufacturer serving food, pharmaceutical, cosmetics and personal/home care for more than four decades.
-
Its colours meet European, US, Chinese and Japanese pharmacopoeia standards.
-
It markets a "One World, One Quality" range. These are high-purity colours designed to comply at once with six regulatory frameworks: JECFA, USA, Europe, Japan, China and India.
-
It operates through wholly owned subsidiaries in the USA, Netherlands, UK and China for local stock and technical support.
-
Its products are Halal, Kosher and REACH compliant.
The full annual-report "Business Overview" text is not publicly accessible. The company's website disallows automated access, and the annual report is filed only with the MCA.
Business model and revenue model
| Revenue model component | Assessment | Basis |
|---|---|---|
| Product sales (B2B manufactured colourants) | Effectively 100% of revenue | ICRA describes operating income from dye/pigment sales; no service or licensing line disclosed |
| Traded/partner-manufactured product | Present but not quantified. Combined capacity includes "partners", which implies some outsourced/toll manufacturing. | ICRA May-2026 |
| Services (custom blending, technical support) | Bundled into product pricing; not separately monetised as far as disclosed | Exhibitor profiles |
| Subscription / licensing | None disclosed | — |
Value-chain position
Neelikon sits in the middle of the chain. Upstream are petrochemical-derived intermediates (aromatic amines, sulphonated naphthalene/benzene derivatives and similar) and, for natural colours, plant extracts. Downstream are formulators and brand owners in food, pharma and cosmetics.
The company performs synthesis, purification to food/pharma-grade specifications, laking (precipitation onto alumina substrates), blending and regulatory certification. In the US, batch certification of FD&C colours by FDA is a gatekeeping step that "USFDA certified" grades must pass.
Customer types and channels
ICRA describes a two-tier go-to-market:
Domestic (India): a strong distributor network, plus direct sales to large food, pharmaceutical and personal-care companies.
Export: direct sales into more than 65 countries, with the company's colours present in more than 100 countries through distribution. ICRA's May-2026 rationale gives both figures. Earlier rationales cite "more than 100 countries" for exports.
ICRA credits the company with low customer concentration and a diversified supplier base.
End-markets served
| End-market | Typical applications | Product families |
|---|---|---|
| Food & beverage | Confectionery, beverages, bakery, dairy, desserts, seasonings, pet food | FD&C dyes, lakes, blends, natural colours (Neelinatural) |
| Pharmaceuticals | Tablet coatings, capsules, syrups | Pharma-grade dyes and lakes, iron oxides, TiO2, TiO2-free alternatives |
| Cosmetics & personal care | Lipsticks, nail, soaps, shampoos | D&C dyes (for example D&C Red 27, D&C Red 33), cosmetic lakes and pigments |
| Home care | Detergents, cleaners | Water-soluble dyes |
| Stationery & inkjet inks | Writing inks, inkjet | Ink-grade dyes |
| Industrial / fluorescent | Daylight fluorescent pigments, specialty applications | Specialty fluorescent dyes |
Independent characterisation
Neelikon is a mid-sized, export-oriented Indian specialty-chemical SME that has built regulatory credentials (multi-jurisdiction compliance, US FDA certification, FSSC 22000) in a niche where those credentials are the main barrier to entry.
ICRA divides the industry into two parts:
-
a commoditised mass-consumption segment with intense Chinese and Indian competition
-
a concentrated value-added segment where a few large players sell direct to end-users
Neelikon's margin recovery from 12.4% (FY2024) to about 17% (FY2026) has been attributed to a richer product mix and higher domestic share. That suggests it is pivoting toward the value-added end.
The business is structurally exposed to the US-led regulatory move away from petroleum-based dyes. That shift is both a threat to its legacy core and an opening for its natural-colour and TiO2-free lines.
Strategy
No annual-report strategy section, investor day or management commentary is publicly accessible. The strategic themes below are inferred from verifiable actions and third-party descriptions.
Observable strategic themes
| Theme | Evidence | Assessment |
|---|---|---|
| Move up the value chain | ICRA cites a "favourable product mix" and value-added products as margin drivers. The Saykha conversion capex targets value-added products. | The main margin lever since FY2024 |
| Global regulatory harmonisation as a selling point | "One World, One Quality" range compliant with six frameworks | Differentiator versus commodity Chinese and Indian suppliers |
| Natural colours diversification | Neelinatural range, marketed at Fi Europe 2025 and in a June-2026 brochure | Defensive and offensive response to synthetic-dye regulation |
| TiO2-free alternatives | Listed in 2025–2026 exhibitor profiles | Response to EU E171 restriction and pharma reformulation |
| Direct market presence | Fourth subsidiary added (USA) | Captures distributor margin; closer to US reformulation demand |
| Domestic mix shift | Higher domestic share supporting FY2026 realisations | Hedge against export price competition |
| Financial conservatism | No term debt; capex fully from internal accruals; no dividends expected | Preserves optionality; ICRA's downgrade trigger is TD/OPBDITA above 1.5x |
Initiatives in the last 24 months (Oct-2024 to Oct-2026)
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Saykha plant reconfiguration capex | Announced by Mar-2025; FY2026–FY2027 | About INR 60 crore to modify the plant for higher value-added products, funded internally. By May-2026 ICRA describes this capex as "being optimised". | ICRA Mar-2025; May-2026 |
| USA subsidiary | By May-2026 | Neelikon Colors Global USA Inc. added to consolidation | ICRA May-2026 |
| Enhanced bank limits | May-2026 | Rated limits raised by INR 30 crore to INR 134.75 crore, signalling expected working-capital growth | ICRA May-2026 |
| Natural colours marketing push | Dec-2025 to Jun-2026 | Fi Europe 2025; Neelinatural brochure | Ingredients Network |
Medium-term targets / guidance
Not publicly disclosed. ICRA's forward view (May-2026) expects stable cash flows, comfortable liquidity, limited repayment obligations and no dividends. It flags West Asia conflict-driven chemical price inflation as a key monitorable.
ESG commitments
ISO 14001 (environmental management) and ISO 45001 (occupational health and safety) certifications are held. No quantified emissions or sustainability targets have been published.
Products & Services
The company does not publish a full price list or launch-year data. The catalogue below is built from exhibitor profiles, ingredient databases (SpecialChem, COPTIS, Ingredients Network) and ICRA descriptions. Pricing is not publicly disclosed for any line; all are sold B2B on negotiated or quoted terms.
Synthetic food, drug & cosmetic colours
| Product line | Description / specification | Target customer | Flagship / named items | Source |
|---|---|---|---|---|
| US FDA-certified FD&C dyes | Water-soluble synthetic dyes batch-certified for US food, drug and cosmetic use | US-bound food, pharma and cosmetic formulators | FD&C range (specific CI numbers not enumerated publicly) | Maghreb Pharma listing |
| D&C dyes | Drug & Cosmetic grade dyes | Cosmetics, personal care | D&C Red 27 (CI 45410), D&C Red 33 (CI 17200) | SpecialChem |
| "Neelicol" branded dyes | Branded synthetic dye range | Food, cosmetics | Neelicol Black PN (CI 28440) | SpecialChem |
| "One World, One Quality" colours | High-purity grades designed to meet JECFA, US, EU, Japan, China and India specifications at once | Multinational food and pharma companies seeking one global SKU | Range name | Maghreb Pharma listing |
| Lakes (aluminium lakes) | Insoluble pigment forms of dyes for oil/fat systems, coatings and tablets | Confectionery, tablet coating, cosmetics | US FDA-certified lakes; cosmetic lakes | Maghreb Pharma; a-leads |
| Granulars | Dust-free granulated colour forms | Food/pharma manufacturers | Not named | Fi Europe listing |
| Water-soluble colours | Standard soluble dyes | Beverages, home care, food | Not named | Exhibitor profiles |
| Oil-soluble colours | Fat- and solvent-soluble dyes | Fats, waxes, cosmetics | Not named | Exhibitor profiles |
| Customised blends | Shade-matched blends of primaries | Brand owners needing specific shades | Bespoke | Exhibitor profiles |
Inorganic pigments and opacifiers
| Product line | Description | Target customer | Source |
|---|---|---|---|
| Iron oxides | Red, yellow and black iron oxide pigments | Pharma coatings, cosmetics | Maghreb Pharma listing |
| Titanium dioxide | White opacifier | Pharma coatings, cosmetics | Maghreb Pharma listing |
| Titanium-dioxide-free alternatives | Opacity systems that replace TiO2, which is no longer authorised as a food additive (E171) in the EU | EU food and pharma reformulators | Maghreb Pharma; Fi Europe listing |
| Cosmetic pigments | Pigments for decorative cosmetics | Colour-cosmetics brands | a-leads; COPTIS |
Natural colours
| Product line | Description | Applications | Latest dated reference | Source |
|---|---|---|---|---|
| Neelinatural | Natural colours extracted from plants, fruits and vegetables; includes custom natural blends. Supplier categories cited include anthocyanins, beetroot red/betanin and carotenes. | Confectionery, bakery, desserts, dairy, seasonings, beverages, pet food, pharma, cosmetics | Brochure dated 22-Jun-2026 | Ingredients Network |
Specialty / industrial
| Product line | Description | Target customer | Source |
|---|---|---|---|
| Specialty fluorescent dyes | Dyes used to make daylight fluorescent pigments and in specialty industrial uses | Pigment makers, industrial users | COPTIS; ICRA |
| Daylight fluorescent pigments | Fluorescent pigment products | Inks, coatings, plastics | a-leads |
| Inkjet ink dyes | High-purity dyes for inkjet formulations | Ink formulators | ICRA; COPTIS |
| Writing ink dyes | Dyes for stationery inks | Stationery makers | ICRA |
Certifications and compliance (cross-portfolio)
ISO 9001, ISO 14001, ISO 45001, FSSC 22000, Halal, Kosher, REACH. The company says its pharma grades meet European, US, Chinese and Japanese pharmacopoeia standards (Maghreb Pharma listing).
Financial Narrative
FY2021 data was not found in any accessible public source, so the five-year window used here is FY2022–FY2026. FY2026 consolidated figures are not yet published; only standalone provisional figures are available.
Gross profit, EPS, dividends per share, balance-sheet line items, capex and cash-flow statements are not publicly disclosed outside MCA filings.
Income statement — consolidated (reported)
Blank = not publicly disclosed. FY2023 PAT discrepancy: 44.6 (Dec-2023 rationale, PAT/OI 10.6%) vs 41.2 (Mar-2025 rationale, PAT/OI 9.8%). The later figure is used for the margin row.
Income statement — standalone (reported)
FY2026 provisional. Source: ICRA May-2026: ### Derived metrics (arithmetic from ICRA ratios — labelled as derived)
How these were derived: EBITDA = operating income × OPBDIT/OI: - Implied interest = EBITDA ÷ interest coverage.
-
Implied debt = EBITDA × Total debt/OPBDIT, using the precise ratios ICRA quotes in text where available (0.71x FY2022, 0.78x FY2023, 0.67x FY2024). Otherwise the rounded table ratio is used (0.7x FY2025 consolidated; 0.4x and 0.6x standalone).
-
Debt figures are rounded approximations. ICRA confirms the company has no long-term debt, so implied debt is essentially working-capital borrowing.
Growth
Revenue CAGR: Consolidated FY2022–FY2025 is about 0.9% a year (452.4 to 464.9). On this evidence, the business has not grown in nominal terms from its FY2022 peak. Recovery since FY2024 has been margin-led rather than volume-led.
Liquidity datapoints
Net debt: Implied FY2026 standalone debt of about INR 32 crore against INR 106.9 crore cash gives an implied net cash of about INR 75 crore. This is a derived approximation.
Items not publicly disclosed
Gross profit; operating income (EBIT); pre-tax income; EPS (basic/diluted); dividends per share; total assets (EMIS reports only +16.5% growth in 2025, without the base); equity/net worth in absolute terms; goodwill and intangibles; working capital in absolute terms; operating cash flow, capex and free cash flow by year (beyond the Saykha capex of about INR 130 crore and planned capex of about INR 60 crore); buybacks; ROE, ROA and ROIC; current ratio; asset turnover; cash conversion cycle. All of these are available in MCA AOC-4 filings, which can be bought through MCA21 or data vendors (EMIS, Tofler).
Commentary on trends, inflections and drivers
FY2022 (peak). A 20.1% OPBDIT margin and INR 70.2 crore PAT on INR 452.4 crore revenue marked the cyclical high. This matches the post-COVID restocking boom across Indian specialty chemicals and peers. For comparison, listed peer Vidhi Specialty reported its highest revenue (about INR 537 crore) in the same year.
FY2023 (inflection down). Revenue fell about 7%. ICRA attributes this to weaker export demand as developed-market macro conditions deteriorated, and to rising supply from Chinese producers. Margin nearly halved to 12.4%, and interest coverage dropped from 57.6x to 19.2x as working-capital borrowing costs rose. The step-down was industry-wide: Vidhi's FY2023 revenue fell about 25%.
FY2024 (trough, stabilisation). Revenue was flat. ICRA describes volume growth offset by lower realisations, with the company passing raw-material deflation through to customers. Margin held at 12.4%, and end-user inventory destocking continued. The Saykha greenfield plant was commissioned in March 2024 at about INR 130 crore, funded entirely from internal accruals. Even so, debt/OPBDIT improved to 0.67x, a sign of strong cash generation.
FY2025 (recovery). Revenue grew about 9.8% to INR 464.9 crore, and margin expanded about 380 basis points to 16.2%. ICRA attributes the improvement to better realisations and a more favourable product mix. PAT rose about 41% to INR 53.7 crore.
FY2026 (margin expansion continues; growth slows). Standalone revenue rose only about 3% to INR 462.8 crore (provisional). Standalone OPBDIT margin, however, reached 17.3%, the highest in the visible series apart from FY2022. ICRA cites a higher share of domestic sales, which carry better realisations, and cost efficiencies. Standalone PAT fell about 8% to INR 46.2 crore despite the higher EBITDA. Likely causes include higher depreciation from the Saykha plant and possibly lower other income or a higher tax rate; this is not disclosed and is inferred only. Cash rose to INR 106.9 crore.
Overall. The company has shown durable cash generation through a full down-cycle while funding a plant equal to about 30% of a year's revenue without term debt. The open question is top-line growth. Revenue is flat versus FY2022, and the Saykha asset is under-utilised.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (As Reported) Overview
| Segment (as reported) | Contents | Segment revenue | Segment margin | Status |
|---|---|---|---|---|
Colourants (single segment, inferred) | Synthetic food/drug/cosmetic dyes, lakes, pigments, iron oxides, TiO2 and alternatives, natural colours, fluorescent dyes, ink dyes | Equals total operating income (see below) | Equals company OPBDIT margin | Inferred; not formally disclosed |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Colourants revenue consolidated (INR Cr) | 452.4 | 421.4 | 423.5 | 464.9 | — |
Colourants revenue standalone (INR Cr) | — | — | 402.7 | 449.2 | 462.8 |
YoY growth consolidated (%) | — | -6.9 | 0.5 | 9.8 | — |
YoY growth standalone (%) | — | — | — | 11.5 | 3.0 |
OPBDIT margin consolidated (%) | 20.1 | 12.4 | 12.4 | 16.2 | — |
OPBDIT margin standalone (%) | — | — | 11.8 | 15.5 | 17.3 |
Group Entities
| Entity | Country | Ownership | Role | Source |
|---|---|---|---|---|
Neelikon Food Dyes and Chemicals Ltd | India | Parent | Manufacturing (Roha, Saykha), domestic and export sales | ICRA |
Shanghai Neelikon Food Dyes & Chemicals Ltd | China | 100% | China sales, stock and technical support | ICRA May-2026 |
Neelikon Food Dyes & Chemicals (Europe) Ltd (trades as Neelikon Specialities Europe Ltd) | UK | 100% | UK/EU sales and stockholding | ICRA; COPTIS |
Neelikon Food Dyes & Chemicals (Netherlands) / Neelikon Specialities Europe B.V. | Netherlands | 100% | EU sales hub; trade-show presence | ICRA; Fi Europe listing |
Neelikon Colors Global USA Inc. | USA | 100% | US sales, stock and support; first consolidated in the May-2026 rationale | ICRA May-2026; EMIS |
Key Financials and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating income (INR Cr) | 452.4 | 421.4 | 423.5 | 464.9 |
PAT (INR Cr, per ICRA Dec-2023) | 70.2 | 44.6 | — | — |
PAT (INR Cr, per ICRA Mar-2025 and May-2026) | — | 41.2 | 38.2 | 53.7 |
OPBDIT margin (%) | 20.1 | 12.4 | 12.4 | 16.2 |
PAT margin (%) | 15.5 | 9.8 | 9.0 | 11.6 |
Key Financials and Margin Analysis (%) (FY2024–FY2026)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Operating income (INR Cr) | 402.7 | 449.2 | 462.8 |
PAT (INR Cr) | 35.3 | 50.1 | 46.2 |
OPBDIT margin (%) | 11.8 | 15.5 | 17.3 |
PAT margin (%) | 8.8 | 11.1 | 10.0 |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA consolidated derived (INR Cr) | 90.9 | 52.3 | 52.5 | 75.3 | — |
EBITDA standalone derived (INR Cr) | — | — | 47.5 | 69.6 | 80.1 |
Implied interest consolidated derived (INR Cr) | 1.6 | 2.7 | 1.3 | 1.5 | — |
Implied total debt consolidated derived (INR Cr) | 64.5 | 40.8 | 35.2 | 52.7 | — |
Implied total debt standalone derived (INR Cr) | — | — | 19.0 | 41.8 | 32.0 |
Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Consolidated revenue growth YoY (%) | -6.9 | 0.5 | 9.8 | — |
Consolidated PAT growth YoY (%, restated base) | -41.3 | -7.3 | 40.6 | — |
Standalone revenue growth YoY (%) | — | — | 11.5 | 3.0 |
Standalone PAT growth YoY (%) | — | — | 41.9 | -7.8 |
Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
TOL/TNW consolidated (x) | 0.4 | 0.3 | 0.2 | 0.3 | — |
TOL/TNW standalone (x) | — | — | 0.2 | 0.3 | 0.2 |
Total debt/OPBDIT consolidated (x) | 0.71 | 0.78 | 0.67 | 0.7 | — |
Total debt/OPBDIT standalone (x) | — | — | 0.4 | 0.6 | 0.4 |
Interest coverage consolidated (x) | 57.6 | 19.2 | 41.7 | 49.9 | — |
Interest coverage standalone (x) | — | — | 39.8 | 50.7 | 46.2 |
Valuation Snapshot
| Metric | Value | As at / period | Source |
|---|---|---|---|
Unencumbered cash (standalone) | INR 67.5 crore | 30-Sep-2023 | ICRA Dec-2023 |
Unencumbered cash (standalone) | INR 86.1 crore | 31-Mar-2024 | ICRA Mar-2025 |
Unencumbered cash (standalone, provisional) | INR 106.9 crore | 31-Mar-2026 | ICRA May-2026 |
Average fund-based limit utilisation | 49% of INR 89 crore limits | 12 months to Aug-2023 | ICRA Dec-2023 |
Average fund-based limit utilisation | 22% of INR 99 crore limits | 12 months to Sep-2024 | ICRA Mar-2025 |
Average fund-based limit utilisation | about 24% of INR 129 crore limits | 12 months to Dec-2025 | ICRA May-2026 |
Fund flow from operations | INR 38–40 crore a year | FY2023–FY2024 (expected similar FY2025–FY2026) | ICRA Mar-2025 |
Cash accruals | INR 50–55 crore a year | Recent years (FY2025–FY2026) | ICRA May-2026 |
Dividend payout | None expected ("no dividend payouts") | Forward-looking | ICRA May-2026 |
Geographic Revenue
| Indicator | Evidence | Source |
|---|---|---|
Export breadth | Direct export sales to more than 65 countries; colours present in more than 100 countries | ICRA May-2026 |
Export weakness FY2023–FY2024 | Subdued export demand and Chinese supply pressure | ICRA Dec-2023 |
Domestic share rising (FY2026) | ICRA cites a higher share of domestic sales commanding better realisations as a margin driver | ICRA May-2026 |
Subsidiary footprint | UK, Netherlands (Europe); Shanghai (China); USA (new) | ICRA May-2026 |
North America route-to-market history | Spectra Colors exclusive US/Canada distributor from 2005; now supplemented or replaced by its own US subsidiary (relationship status today not publicly disclosed) | Happi 2005; ICRA May-2026 |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable (unlisted) |
Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B) | Not applicable / not publicly disclosed |
Dividend history | Not publicly disclosed; ICRA expects no dividend payouts going forward |
Buyback authorisations | None disclosed |
Analyst Ratings & Targets
| Date | Long-term rating | Short-term rating | Total rated (INR Cr) |
|---|---|---|---|
30-Jun-2021 | A+ (Stable) | A1 | — |
27-Sep-2022 | A+ (Stable) | A1 | — |
17-Nov-2022 | A+ (Stable) | A1 | — |
21-Dec-2023 | A+ (Stable) | A1 | 104.75 |
17-Mar-2025 | A+ (Stable) | A1 | 104.75 |
25-May-2026 | A+ (Stable) | A1+ (upgraded) | 134.75 |
“—” = not publicly disclosed.
Debt Facilities
| Facility | Amount (INR Cr) | Rating |
|---|---|---|
Long-term fund-based cash credit | 15.00 | A+ (Stable) |
Short-term fund/non-fund based WC limits | 116.50 | A1+ |
LT/ST fund/non-fund based others (sub-limit) | (131.50) | A+ (Stable)/A1+ |
Short-term non-fund based forward cover | 3.25 | A1+ |
Total | 134.75 | — |
Capital Markets Data
| Metric | FY2024 | FY2025 | FY2026 | FY2027 |
|---|---|---|---|---|
Total rated bank limits (INR Cr) | 104.75 | 104.75 | 104.75 | 134.75 |
Analyst Conclusions
Management guidance
Not publicly disclosed. ICRA's stable outlook rests on its expectation of stable cash flow from operations, comfortable liquidity, limited repayments and no dividend outflows. It names the West Asia-driven chemical price run-up as a monitorable.
Consensus
None; no sell-side coverage.
Bull case
-
The margin structure has reset higher. OPBDIT moved from 12.4% to about 17% in two years on mix and domestic share, and EBITDA reached about INR 80 crore in FY2026 (standalone, derived). If Saykha's value-added conversion delivers, margins near 18–20% (FY2022-like) are plausible without heavy volume growth.
-
Regulation can be monetised. The FDA phase-out pushes US brand owners toward natural colours. With Neelinatural, TiO2-free lines, multi-jurisdiction compliance and a new US subsidiary, Neelikon is positioned to capture reformulation spend rather than only lose synthetic volume.
-
The balance sheet is a strategic weapon. With about INR 107 crore of cash, about INR 75 crore implied net cash and coverage near 50x, the company can fund natural-colour capacity or acquire a natural-extraction business without equity dilution. ICRA's downgrade trigger (above 1.5x TD/OPBDITA) leaves room for meaningful debt-funded growth if needed.
Bear case
-
Structural decline in the core. Petroleum-based synthetic dyes are Neelikon's historic franchise. US food use is being phased out, FDA scrutiny has spread to drugs, and Congress is legislating. Natural colours are a different business, with agricultural sourcing, lower purity control and different leaders (Oterra, Sensient, Givaudan), where Neelikon has no demonstrated scale.
-
No growth for four years. FY2025 consolidated revenue (INR 464.9 crore) barely exceeds FY2022's, and FY2026 standalone growth was about 3%. The listed peer just posted +66% quarterly growth, which raises the question of whether Neelikon is losing share in the China+1 window.
-
Capital-allocation execution. About INR 130 crore was spent on Saykha, ICRA judged the ramp-up sub-optimal, and another INR 60 crore was earmarked to fix it. Combined with PAT falling in FY2026 despite higher EBITDA, returns on recent capex appear weak. Opaque disclosure makes this hard to monitor.
Key catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Expected timing |
|---|---|---|
| FY2026 audited consolidated results (MCA / next ICRA review) | Confirms provisional margin and the PAT trajectory; first full year with the US subsidiary | Late 2026 to 2027 |
| US FDA end-2026 phase-out deadline and any Congressional statute | Determines US synthetic food-dye volume loss | Dec-2026 onward |
| Saykha utilisation and conversion capex completion | Return on about INR 190 crore of cumulative investment | FY2027 |
| Natural colours revenue disclosure (if any) | Evidence of pivot traction | Ongoing |
| West Asia conflict / chemical input prices | Margin risk given high inventory | Ongoing |
| Use of enhanced bank limits (INR 134.75 crore) | Signals working-capital build for growth | FY2027 |
| Peer (Vidhi) growth versus Neelikon | Market-share signal | Quarterly |
| Next ICRA surveillance | Possible long-term upgrade if scale improves | About mid-2027 |
Concluding analyst verdict
Neelikon Food Dyes and Chemicals is a financially disciplined, promoter-run specialty colourant maker whose credit quality is clearly better than its growth profile. The evidence is consistent across three ICRA reviews.
The company came through a severe FY2023–FY2024 industry downturn without stress. It funded a INR 130 crore greenfield plant entirely from internal accruals, kept zero term debt, and emerged with record cash (INR 106.9 crore) and an upgraded A1+ short-term rating. Margin recovery to about 17% shows that the value-added and domestic-mix strategy works.
The equity-style questions are less comfortable. Revenue has been essentially flat since FY2022, and the new Saykha capacity needed a second round of capex after a weak ramp-up. Standalone PAT fell in FY2026 even as EBITDA rose. Above all, the US is moving decisively to remove petroleum-based synthetic dyes from food, with signs of spill-over into drugs and the possibility of statute. For a company built on certified synthetic colours, that is a franchise-level change, not a cyclical one.
Neelikon has responded sensibly with Neelinatural, TiO2-free lines, multi-jurisdiction products and a US subsidiary. However, no public data shows how much of revenue these new lines represent. Natural colours are also a crowded field with well-capitalised incumbents.
Verdict: From a credit perspective Neelikon is low-risk and stable to improving. From a strategic and equity perspective it is a "show-me" story. Its balance sheet buys time and options. Its future value depends on turning regulatory disruption into natural- and clean-label colour growth before synthetic volumes erode. Investors, counterparties or acquirers should obtain the FY2025–FY2026 MCA filings for segment, geographic and product-mix data before forming a firmer view, because public disclosure is too thin for higher-conviction conclusions.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title / role | Tenure | Background | Source |
|---|---|---|---|---|
Mukund Turakhia | Founder and promoter | Since 1983 | Chemical engineer; over 50 years in the dyestuff and chemical industry | ICRA rationales |
Satyen Turakhia | Director | — | Not disclosed (presumed promoter family) | a-leads aggregator |
“—” = not publicly disclosed.
Major Shareholders
| Holder category | Stake | Source |
|---|---|---|
Promoter family (Turakhia) / natural persons | Not publicly disclosed; LEI records the ultimate parent as natural persons, with no corporate parent | Bloomberg LEI |
Institutional investors | None identified; no PE/VC funding rounds found | — |
Top-10 holders | Not applicable / not publicly disclosed | — |
Competitive Landscape
Key Competitors
| Competitor | HQ | Listing | Overlap with Neelikon | Revenue (latest available) | Source / note |
|---|---|---|---|---|---|
Vidhi Specialty Food Ingredients Ltd | Mumbai, India | BSE: 531717 | Synthetic food colours, natural colours; describes itself as the 2nd-largest food colour maker in Asia and 3rd-largest globally; also a Roha MIDC presence | INR 380.0 crore (FY2026, consolidated) | Exchange filings via 5paisa / StockAnalysis |
Sensient Technologies (Sensient Colors) | Milwaukee, USA | NYSE: SXT | Food, pharma and cosmetic colours, synthetic and natural; global leader in value-added colours | — | Named as a major food dye producer in Nexstar reporting |
Oterra (formerly Chr. Hansen Natural Colors) | Copenhagen, Denmark | Private | Natural colours | — | Oterra press releases |
Roha Dyechem | Mumbai, India | Private | Synthetic and natural food colours, lakes | — | — |
Koel Colours | Mumbai, India | Private | Food, drug and cosmetic colours | — | — |
Dynemic Products Ltd | Ahmedabad, India | Listed (BSE/NSE) | Food colours and lakes | — | Industry knowledge |
Chinese synthetic food colour producers (multiple) | China | Various | Mass-consumption synthetic colours | — | ICRA cites rising Chinese supply |
Givaudan (natural colours, through acquired businesses) | Switzerland | SIX | Natural colours | — | Industry knowledge |
Pharma coating / colour specialists (for example Colorcon) | USA | Private | Pharma colours, TiO2-free coatings | — | Industry knowledge |
Fluorescent pigment makers (for example DayGlo / Sun Chemical) | USA | Private (DIC group) | Fluorescent dyes and pigments (customer and competitor) | — | Industry knowledge |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Neelikon revenue consolidated (INR Cr) | 452.4 | 421.4 | 423.5 | 464.9 | — |
Vidhi revenue (INR Cr) | 537.1 | 404.0 | 298.0 | 382.3 | 380.0 |
Neelikon OPBDIT margin (%) | 20.1 | 12.4 | 12.4 | 16.2 | — |
Vidhi operating income margin (%) | 15.3 | 13.0 | 17.2 | 15.9 | 18.1 |
Neelikon PAT (INR Cr) | 70.2 | 41.2 | 38.2 | 53.7 | — |
Vidhi PAT (INR Cr) | 58.6 | 37.7 | 36.4 | 43.4 | 49.0 |
Recent Developments
Material industry and regulatory events that directly affect the company are included and flagged (Industry).



